Today’s pharmaceutical industry requires stakeholders to continually assess the current status and anticipate future changes. PharmExec.com highlights the following trends to watch in 2018 in the pharma and biotech space.
- Though efforts to repeal the Affordable Care Act failed in 2017, the removal of the individual mandate requirement might reduce by millions the number of Americans with health care coverage and drive up premiums.
- 2018 is expected to see a widespread creep of copay accumulators, as copay programs’ enrollments are poised to surge. While PBMs are getting aggressive in combating copay subsidies, manufacturers might see a significant increase in their total copay budget. They must learn to work with cost control measures, or reduce or eliminate copay programs.
- Many low-cost medications are entering the specialty pharmacy channel, which might cause a downstream financial strain and impact other stakeholders within the channel.
- Gene therapy, an extremely expensive but effective treatment option, poses new challenges to all stakeholders in the industry. The manufacturers, specialty pharmacies and payers might collaborate to come up with sustainable economic models.
- Pharma companies also should better understand healthcare consumers’ willingness to comparison shop and develop information and decision support tools to help consumers navigate the information.
Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.